Sign In
Buy MDGL
$513.43
+0.550 (+0.107%)
At Close: Jun 23, 2026
The 3 Most Undervalued Biotech Stocks to Buy: November 2023
10:56am, Tuesday, 14'th Nov 2023
These companies in the biotechnology sector are doing incredible work and achieving wonderful developments. The result is not not only growth and profit for the companies, but they are also offering e
Madrigal Pharmaceuticals Bolstered By $500 Million Equity Infusion Is A 'Buy' Into 2024
03:19am, Sunday, 05'th Nov 2023
Madrigal Pharmaceuticals is transitioning from clinical trials to market-ready solutions for non-alcoholic steatohepatitis (NASH) and liver fibrosis. Their leading candidate, Resmetirom, is in Phase I
2 Risky Stocks With Massive Potential
09:53am, Tuesday, 17'th Oct 2023
Recursion Pharmaceuticals is looking to introduce a paradigm shift in the way biotechs develop drugs. Madrigal Pharmaceuticals developed a therapy for a disease that has eluded many of its larger peer
Madrigal (MDGL) to Raise Capital Via Public Offering of $500M
01:31pm, Monday, 02'nd Oct 2023
Madrigal (MDGL) is raising funds through a public offering of 1.25 million shares of its common stock to use in commercial activities in the preparation of a potential launch of resmetirom in the Unit
Wall Street Thinks Madrigal Pharmaceuticals Could Climb 93%. Here's Why It Could Happen Soon.
09:53am, Wednesday, 27'th Sep 2023
Analysts have high hopes for Madrigal Pharmaceuticals over the coming year. Its drug resmetirom seems effective for a liver disease, non-alcoholic steatohepatitis.
Madrigal (MDGL) Gains on NDA for NASH Therapy Acceptance by FDA
09:01am, Thursday, 14'th Sep 2023
Madrigal (MDGL) gains as new drug application for resmeritom to treat nonalcoholic steatohepatitis gets accepted by the FDA in the United States.
Madrigal Pharmaceuticals shares fall after new CEO named
08:32am, Monday, 11'th Sep 2023
Shares of Madrigal Pharmaceuticals Inc. MDGL, +2.91% fell more than 7% premarket on Monday after the company appointed Bill Sibold, a former Sanofi SNY, +1.06% executive, as its new CEO. Sibold succee
The 3 Best Biotech Stocks to Buy Now: September 2023
03:43pm, Monday, 04'th Sep 2023
Biotech stocks have underperformed in the U.S. stock market by a wide margin this year. The sector's most popular index, the iShares Biotechnology ETF (NASDAQ: IBB ), is down 5% since Jan. 27.
3 Biotech Stocks That Wall Street Analysts Can't Get Enough Of
08:54am, Wednesday, 30'th Aug 2023
This year has not been kind to biotech stocks, as the sector's most popular ETF, the iShares Biotechnology ETF (NASDAQ: IBB ), has fallen about 3% so far in 2023. Investors are probably worried about
The 3 Most Promising Pharma Stocks to Own Now
05:20am, Wednesday, 30'th Aug 2023
It is remarkable that day after day there are pharmaceutical companies working hard, researching and developing high-tech medicines for the improvement of human health and the treatment of severe dise
Madrigal's Resmetirom Nears Commercialization Despite Market Concerns
10:27am, Sunday, 20'th Aug 2023
Madrigal Pharmaceuticals is developing resmetirom, a drug for non-alcoholic steatohepatitis and fatty liver disease, with promising trial results. Madrigal has a strong cash position and manageable de
Madrigal: With Successful NASH Study, Possible Accelerated Approval Is Next
05:30pm, Thursday, 13'th Jul 2023
Madrigal Pharmaceuticals, Inc. dual surrogate Primary endpoint being met in phase 3 MAESTRO-NASH study allowed for the rolling NDA submission of resmetirom for the treatment of patients with NASH. Pot
Madrigal Pharmaceuticals' stock up 5% as company starts rolling submission for FDA approval of NASH treatment
12:28pm, Friday, 30'th Jun 2023
Madrigal Pharmaceuticals Inc.'s stock MDGL, +5.00% rose 5% Friday after the company said it has started a rolling submission of a New Drug Application to the U.S. Food and Drug Administration seeking
Weight-loss drugs in development aim to replace injections with pills
03:21pm, Monday, 26'th Jun 2023
Wall Street's obsession with next-generation obesity and diabetes treatments intensified over the weekend as drugmakers presented new clinical-trial data on the drugs — including weight-loss pills i
2 Growth Stocks That Doubled in 2023 and Could Shoot 55% to 87% Higher, According to Wall Street
05:38am, Tuesday, 30'th May 2023
Two stocks in the healthcare sector have already doubled this year, and they could climb much higher, according to Wall Street. Viking Therapeutics is a clinical-stage biotech with an experimental tre
